EMA reviewing empagliflozin MAA

EMA accepted for review an MAA from Boehringer Ingelheim GmbH (Ingelheim, Germany) for empagliflozin to treat Type II diabetes. The company, which submitted an NDA to FDA for the product on Monday, is...